Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
Xolatryp's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for Xolatryp. Showing past 6 months and next 12 months · 1 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| Xolatryp | Nyrada | Small Molecule Other | Phase 2 | 0 | ||||
| Effect of L-Carnitine on Biomarkers of Myocardial Reperfusion Injury in Patients With STEMI | Ain Shams University | — | Phase 2 |
Read-across commentary attached per trial. Phase ordering preserved within each group.
External analyst notes, journalism, and industry commentary cited with attribution.
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| — |
| — |
| — |
| — |
| — |
| Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction | Nyrada Pty Ltd | — | Phase 2 | — | — | — | — | — |